Ignite Creation Date:
2025-12-25 @ 2:15 AM
Ignite Modification Date:
2025-12-26 @ 12:44 AM
Study NCT ID:
NCT05253560
Status:
RECRUITING
Last Update Posted:
2023-11-24
First Post:
2021-11-11
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Prodromal Parkinsonian Features in GBA1 Mutation Carriers
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D005776', 'term': 'Gaucher Disease'}], 'ancestors': [{'id': 'D013106', 'term': 'Sphingolipidoses'}, {'id': 'D020140', 'term': 'Lysosomal Storage Diseases, Nervous System'}, {'id': 'D020739', 'term': 'Brain Diseases, Metabolic, Inborn'}, {'id': 'D001928', 'term': 'Brain Diseases, Metabolic'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D008661', 'term': 'Metabolism, Inborn Errors'}, {'id': 'D030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D009358', 'term': 'Congenital, Hereditary, and Neonatal Diseases and Abnormalities'}, {'id': 'D008064', 'term': 'Lipidoses'}, {'id': 'D008052', 'term': 'Lipid Metabolism, Inborn Errors'}, {'id': 'D016464', 'term': 'Lysosomal Storage Diseases'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D052439', 'term': 'Lipid Metabolism Disorders'}]}}, 'protocolSection': {'designModule': {'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'Blood sample for DNA sequencing and biomarker analysis'}, 'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'CROSS_SECTIONAL', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 600}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2017-05-16', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2023-11', 'completionDateStruct': {'date': '2025-12-31', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2023-11-22', 'studyFirstSubmitDate': '2021-11-11', 'studyFirstSubmitQcDate': '2022-02-21', 'lastUpdatePostDateStruct': {'date': '2023-11-24', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2022-02-24', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-01-16', 'type': 'ESTIMATED'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Transcranial sonography (TCS)', 'timeFrame': '8 years', 'description': 'Transcranial sonography (TCS) is a useful noninvasive diagnostic tool to detect hyperechogenicity (SN+) of the substantia nigra area in the brain. The hyperechogenicity happens due to increased amounts of iron, reflecting a functional impairment.'}, {'measure': 'Color discrimination test', 'timeFrame': '8 years', 'description': 'Color discrimination was analyzed using The Farnsworth-Munsell 100 hue test. The test includes four boxes with a fixed number of color shade caps with slight shade differences needed to be ordered correctly. The result of each box was entered into a computerized system and automated the total error score (TES)'}, {'measure': 'Hyposmia by the Bit-A UPSIT smell test', 'timeFrame': '8 years', 'description': 'The shorter version of the UPSIT smell test (The University of Pennsylvania Smell Identification Test) was used to evaluate hyposmia using twelve cards, each with a different smell.'}, {'measure': 'Orthostatic hypotension (OH)', 'timeFrame': '8 years', 'description': 'defined as a fall of at least 20 mmHg systolic or at least ten mmHg diastolic blood pressure by 3 min of active standing or head-up tilt'}, {'measure': 'Montreal Cognitive Assessment (MoCA)', 'timeFrame': '8 years', 'description': 'evaluate the cognitive and mental aspects associated with PD. A Montreal Cognitive Assessment (MoCA) score of 26 and above was considered normal'}, {'measure': 'NeuroTrax computerized battery.', 'timeFrame': '8 years', 'description': 'The NeuroTrax computerized battery (www.neurotrax.com) includes seven sections: memory, executive function, attention, information processing speed, visual-spatial, verbal function, and motor skills'}, {'measure': 'Beck Depression Inventory', 'timeFrame': '8 years', 'description': 'self-administered questioner including 21 questions used to screen, diagnose, and measure the severity of depression.'}, {'measure': 'Frontal lobe assessment battery (FAB).', 'timeFrame': '8 years', 'description': 'evaluates executive dysfunction'}, {'measure': 'rapid eye movement (REM)', 'timeFrame': '8 years', 'description': 'Idiopathic rapid eye movement sleep behavior disorder is an important risk factor in the diagnosis of PD. The REM questionnaire was completed by the participant.'}, {'measure': 'Epworth sleepiness scale (ESS)', 'timeFrame': '8 years', 'description': 'assessing daytime sleepiness includes an eight-question questionnaire scoring between 0 and 24; the higher the score, the higher the chances of dosing off'}, {'measure': 'Perdue pegboard.', 'timeFrame': '8 years', 'description': 'Perdue pegboard measures the movement of fingers, hands, and arms in 4 different tasks, testing motor abilities and coordination by placing as many pegs and discs on a board in three 30 seconds trials for each subset and three 60 second trials for the assembly subset'}, {'measure': 'UPDRS part III.', 'timeFrame': '8 years', 'description': 'measures gross motor function. A score above 6, not including postural and action tremor, was considered abnormal'}, {'measure': 'The Timed Up and Go (iTUG).', 'timeFrame': '8 years', 'description': "The Timed Up and Go (iTUG) (EncephaLogTM) is a platform that utilizes smartphones' internal motion sensors for conducting motor evaluation including general walking score, step to step persistency, hand sway and rotation time."}, {'measure': 'Questionnaire regarding risk factors', 'timeFrame': '8 years', 'description': 'Spontaneous bowel movement frequency was used to define constipation. Urinary and erectile dysfunction were assessed according to the MDS criteria'}], 'primaryOutcomes': [{'measure': "Building a model to identify carriers of Gaucher disease prone to Parkinson's disease, using tests to assess different domains of PD, including anatomy, cognitive and mental, sleep disorder, and motor.", 'timeFrame': '8 Years', 'description': 'Carriers of a variant in the GBA1 gene (GBA carriers) are at the highest risk of developing Parkinson disease (PD). A screening study for prodromal PD features in a cohort of obligatory GBA carriers between 40-75 years was initiated to identify candidates for a PD prevention trial. We added healthy controls and GD patients in order to determine the incidence of prodromal PD and for analyzing the differences between the two groups helping to build a model for identifying at risk PD at the prodromal stage.\n\nParticipants preform 15 pre-defined non-invasive tests for prodromal PD and assessment of risk factors. Risk factors for PD included age, sex, type of GBA1 variant, coffee and tea caffeine consumption, smoking habits, exposure to solvents and pesticides, and family history of PD (1st and/or 2nd degree relatives with PD).'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'conditions': ['Gaucher Disease, Type 1', 'Healthy']}, 'descriptionModule': {'briefSummary': "Objective of the trial. To define a sub-population which is at increased risk of developing Parkinson, beyond the fact of carrying Gaucher; in this sub-population the investigators shall conduct a comprehensive evaluation that includes a variety of non-invasive tests, whose purpose is to evaluate the state of the pre- Parkinson's disease signs, signs which can appear, even twenty years before the appearance of the disease, and also to compare them to a group of diagnosed Gaucher patients and a group of healthy people who are not carriers of Gaucher disease.\n\nA group of those carriers will be available for trial or for treatment, if there will be a medicine for the prevention of the development of Parkinson, obtainable.", 'detailedDescription': 'The carriers, the healthy people and the Gaucher patients will undergo a number of non-invasive tests, which test the pre-Parkinson signs.\n\nThe tests are based on various sense tests, blood tests, measuring of blood pressure, lying and standing, ultra-sound of the brain and a neurological test (test of the nervous system and various questionnaires).'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '75 Years', 'minimumAge': '40 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'Carriers of Gaucher disease mutation Gaucher patients Healthy controls', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Willing to participate\n\nExclusion Criteria:\n\n* PD patients\n* Dementia'}, 'identificationModule': {'nctId': 'NCT05253560', 'briefTitle': 'Prodromal Parkinsonian Features in GBA1 Mutation Carriers', 'organization': {'class': 'OTHER', 'fullName': 'Shaare Zedek Medical Center'}, 'officialTitle': 'Prodromal Parkinsonian Features in GBA1 Mutation Carriers', 'orgStudyIdInfo': {'id': 'SZMC-0168-17'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Carriers of Gaucher disease', 'description': 'Family of patients with Gaucher disease, sequenced for the GBA1 gene.', 'interventionNames': ['Diagnostic Test: The investigators aim to identify prodromal PD in a cohort of carriers of Gaucher disease.']}, {'label': 'Gaucher patients', 'description': 'Patients from the Gaucher clinic in Shaare Zedek Medical Center, Jerusalem, Israel', 'interventionNames': ['Diagnostic Test: The investigators aim to identify prodromal PD in a cohort of carriers of Gaucher disease.']}, {'label': 'Healthy controls', 'description': 'Family members of Gaucher patients who are not carriers of Gaucher disease', 'interventionNames': ['Diagnostic Test: The investigators aim to identify prodromal PD in a cohort of carriers of Gaucher disease.']}], 'interventions': [{'name': 'The investigators aim to identify prodromal PD in a cohort of carriers of Gaucher disease.', 'type': 'DIAGNOSTIC_TEST', 'description': 'Tests to help identify prodromal PD in a cohort of carriers of Gaucher disease', 'armGroupLabels': ['Carriers of Gaucher disease', 'Gaucher patients', 'Healthy controls']}]}, 'contactsLocationsModule': {'locations': [{'zip': '9103102', 'city': 'Jerusalem', 'state': 'Please Select...', 'status': 'RECRUITING', 'country': 'Israel', 'contacts': [{'name': 'Ari Zimran, M.D.', 'role': 'CONTACT', 'email': 'azimran@gmail.com', 'phone': '+97226555143'}, {'name': 'Michal Becker- Cohen, M.Sc.', 'role': 'CONTACT', 'email': 'michalbec@gmail.com', 'phone': '+97226555143'}, {'name': 'Ari Zimran, Prof.', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Michal Becker- Cohen', 'geoPoint': {'lat': 31.76904, 'lon': 35.21633}}], 'centralContacts': [{'name': 'Ari Zimran, MD', 'role': 'CONTACT', 'email': 'azimran@gmail.com', 'phone': '+972-509149149'}, {'name': 'Michal Becker- Cohen, M.Sc.', 'role': 'CONTACT', 'email': 'michalbec@gmail.com', 'phone': '+972-504606310'}], 'overallOfficials': [{'name': 'Ari Zimran, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Shaare Zedek Medical Center'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Shaare Zedek Medical Center', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Prof.', 'investigatorFullName': 'Ari Zimran', 'investigatorAffiliation': 'Shaare Zedek Medical Center'}}}}